Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA single 2.5mg Mounjaro dose is 0.5ml. Each pre-filled KwikPen contains four doses totalling 2ml, which is why each weekly injection delivers exactly that half-millilitre volume regardless of the dose strength. That volume is fixed across all Mounjaro strengths — what changes between the 2.5mg, 5mg, 7.5mg and higher-dose pens is the concentration of tirzepatide in the same 0.5ml. Mounjaro is a prescription-only medicine requiring clinical assessment before it can be prescribed; the pen's volume is a technical specification, not something you adjust yourself.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro KwikPen is designed around a fixed injection volume. Each pen holds 2ml of solution and is divided into four equal weekly doses of 0.5ml each. Eli Lilly uses this approach because a consistent volume makes the device simpler and more reliable, there is no dial to set, no measurement to second-guess.
What changes across the six licensed UK strengths is the concentration of tirzepatide in that 0.5ml. The 2.5mg pen holds 5mg of tirzepatide per ml, giving 2.5mg in each 0.5ml dose. The 5mg pen holds 10mg per ml, so the same half-millilitre delivers 5mg. The pattern continues up to 15mg per dose at the top of the schedule.
This is why you will sometimes see the question asked slightly differently (how many mls are in a single Mounjaro dose) and the answer is always the same 0.5ml, whatever strength you are on. The pen handles the maths; you simply inject as instructed and dispose of the needle safely.
One practical note: keep the pen in the fridge door between uses, where the temperature stays consistently between 2°C and 8°C, and bring it to room temperature for a short time before injecting, exactly how long is specified in the Patient Information Leaflet that comes with your pen, and that leaflet is the right place to check rather than a general website.
For the vast majority of people prescribed Mounjaro, no. The pen is pre-filled and pre-set; there is nothing to draw up, measure or calculate. You attach a new needle, prime if instructed by the leaflet, inject subcutaneously into your abdomen, thigh or upper arm, and the device delivers precisely 0.5ml. That is the end of the dosing step.
The volume becomes relevant if you are ever prescribed a compounded or unlicensed form of tirzepatide, which is a different clinical and legal situation entirely. Licensed Mounjaro pens from an MHRA-regulated supply chain require no syringe work at all. If you have been given a vial and told to draw up 2.5mg of tirzepatide yourself, that is a sign the product is not the licensed Mounjaro pen, and it is worth discussing with your prescriber what you have been supplied.
The 0.5ml per dose figure is published in the Mounjaro Summary of Product Characteristics on the electronic Medicines Compendium (eMC), which is the authoritative reference for prescribers and pharmacists on exactly what each pen contains.
Tirzepatide is a dual GIP and GLP-1 receptor agonist, it activates two gut-hormone pathways involved in appetite regulation and blood-sugar control. Treatment always begins at 2.5mg because the body needs time to adapt to those effects. Nausea, which is the most commonly reported early side effect, tends to be milder when the medicine is introduced gradually. Think of the first four weeks as an adjustment phase rather than a treatment phase.
Dose increases after that are made by your prescriber, typically in four-week steps through 5mg, 7.5mg and higher strengths as clinically appropriate. The 5mg dose is usually where meaningful appetite reduction becomes noticeable for most people. Clinical trial data published in the New England Journal of Medicine showed average weight reductions of around 20 to 21 percent at the 15mg maintenance dose over 72 weeks, which gives some context for why the titration schedule exists, the goal is to reach the dose that works, at a pace the body can manage.
Your prescriber sets the pace. Changing doses early, skipping doses, or splitting a pen to extend supply are all things the Patient Information Leaflet advises against, and our prescribers at nume review each patient's progress before any repeat prescription is issued. You can read about how private treatment is structured on our treatment overview page. For questions about how the cost of treatment fits into the wider picture, the Eli Lilly UK price change context page explains what has happened to Mounjaro pricing since mid-2025.
If you have specific questions about your own dose schedule, our clinical team (including our lead prescriber Mostafa Damghani) is available for aftercare support seven days a week. Or, if you are exploring whether Mounjaro is right for you, our weight-loss treatment overview sets out the full picture before you commit to anything.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.